Functional magnetic resonance: Biomarkers of response in breast cancer

Breast Cancer Research

Volumn 13, Issue 1, 2011, Pages

  O'Flynn, Elizabeth A M ^a   deSouza, Nandita M ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ECHOVIST; GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOFOSVESET; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOTERIDOL; GADOVERSETAMIDE; OXYGEN; TUMOR MARKER;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; DRUG DISTRIBUTION; DRUG PENETRATION; ELASTOGRAPHY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXYGEN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; BREAST TUMOR; FEMALE; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS;

BREAST NEOPLASMS; ELASTICITY IMAGING TECHNIQUES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861438144     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2815     Document Type: Review

References (52)

1. Sardanelli F, Boetes C, Borisch B, Decker T, Federico M, Gilbert FJ, Helbich T, Heywang-Köbrunner SH, Kaiser WA, Kerin MJ, Mansel RE, Marotti L, Martincich L, Mauriac L, Meijers-Heijboer H, Orecchia R, Panizza P, Ponti A, Purushotham AD, Regitnig P, Del Turco MR, Thibault F, Wilson R. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer 2010, 46:1296-1316. 10.1016/j.ejca.2010.02.015, 20304629.
2. Swain SM, Sorace RA, Bagley CS, Danforth DN, Bader J, Wesley MN, Steinberg SM, Lippman ME. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 1987, 47:3889-3894.
3. Kuhl CK. Current status of breast MR imaging. Part 2. Clinical applications. Radiology 2007, 244:672-691. 10.1148/radiol.2443051661, 17709824.
4. Warner E, Plewes DB, Shumak RS, Catzavelos GC, Di Prospero LS, Yaffe MJ, Goel V, Ramsay E, Chart PL, Cole DE, Taylor GA, Cutrara M, Samuels TH, Murphy JP, Murphy JM, Narod SA. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 2001, 19:3524-3531.
5. Fischer DR, Baltzer P, Malich A, Wurdinger S, Freesmeyer MG, Marx C, Kaiser WA. Is the "blooming sign" a promising additional tool to determine malignancy in MR mammography?. Eur Radiol 2004, 14:394-401. 10.1007/s00330-003-2055-9, 14517688.
6. Jinguji M, Kajiya Y, Kamimura K, Nakajo M, Sagara Y, Takahama T, Ando M, Rai Y, Sagara Y, Ohi Y, Yoshida H. Rim enhancement of breast cancers on contrast-enhanced MR imaging: relationship with prognostic factors. Breast Cancer 2006, 13:64-73. 10.2325/jbcs.13.64, 16518064.
7. Malich A, Fischer DR, Wurdinger S, Boettcher J, Marx C, Facius M, Kaiser WA. Potential MRI interpretation model: differentiation of benign from malignant breast masses. AJR Am J Roentgenol 2005, 185:964-970. 10.2214/AJR.04.1073, 16177416.
8. Fischer DR, Malich A, Wurdinger S, Boettcher J, Dietzel M, Kaiser WA. The adjacent vessel on dynamic contrast-enhanced breast MRI. AJR Am J Roentgenol 2006, 187:W147-W151. 10.2214/AJR.05.0377, 16861503.
9. Kuhl CK, Mielcareck P, Klaschik S, Leutner C, Wardelmann E, Gieseke J, Schild HH. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions?. Radiology 1999, 211:101-110.
10. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999, 10:223-232. 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S, 10508281.
11. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging 2002, 16:407-422. 10.1002/jmri.10176, 12353256.
12. Ah-See ML, Makris A, Taylor NJ, Harrison M, Richman PI, Burcombe RJ, Stirling JJ, d'Arcy JA, Collins DJ, Pittam MR, Ravichandran D, Padhani AR. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2008, 14:6580-6589. 10.1158/1078-0432.CCR-07-4310, 18927299.
13. Pickles MD, Lowry M, Manton DJ, Gibbs P, Turnbull LW. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 2005, 91:1-10. 10.1007/s10549-004-5819-2, 15868426.
14. O'Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007, 96:189-195. 2359994, 17211479, 10.1038/sj.bjc.6603515.
15. Padhani AR, Hayes C, Assersohn L, Powles T, Makris A, Suckling J, Leach MO, Husband JE. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology 2006, 239:361-374. 10.1148/radiol.2392021099, 16543585.
16. Manton DJ, Chaturvedi A, Hubbard A, Lind MJ, Lowry M, Maraveyas A, Pickles MD, Tozer DJ, Turnbull LW. Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer 2006, 94:427-435. 2361138, 16465174, 10.1038/sj.bjc.6602948.
17. Yu HJ, Chen JH, Mehta RS, Nalcioglu O, Su MY. MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy. J Magn Reson Imaging 2007, 26:615-623. 10.1002/jmri.21060, 17729334.
18. Hayward JL, Rubens RD, Carbone PP, Heuson JC, Kumaoka S, Segaloff A. Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland. Eur J Cancer 1978, 14:1291-1292.
19. Henderson E, Rutt BK, Lee TY. Temporal sampling requirements for the tracer kinetics modeling of breast disease. Magn Reson Imaging 1998, 16:1057-1073. 10.1016/S0730-725X(98)00130-1, 9839990.
20. Parker GJ, Roberts C, Macdonald A, Buonaccorsi GA, Cheung S, Buckley DL, Jackson A, Watson Y, Davies K, Jayson GC. Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med 2006, 56:993-1000. 10.1002/mrm.21066, 17036301.
21. Kovar DA, Lewis M, Karczmar GS. A new method for imaging perfusion and contrast extraction fraction: input functions derived from reference tissues. J Magn Reson Imaging 1998, 8:1126-1134. 10.1002/jmri.1880080519, 9786152.
22. Norris DG. The effects of microscopic tissue parameters on the diffusion weighted magnetic resonance imaging experiment. NMR Biomed 2001, 14:77-93. 10.1002/nbm.682, 11320535.
23. Le BD, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988, 168:497-505.
24. Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, Dzik-Jurasz A, Ross BD, Van Cauteren M, Collins D, Hammoud DA, Rustin GJ, Taouli B, Choyke PL. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009, 11:102-125. 2631136, 19186405.
25. deSouza NM, Riches SF, Vanas NJ, Morgan VA, Ashley SA, Fisher C, Payne GS, Parker C. Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol 2008, 63:774-782. 10.1016/j.crad.2008.02.001, 18555035.
26. Woodhams R, Matsunaga K, Kan S, Hata H, Ozaki M, Iwabuchi K, Kuranami M, Watanabe M, Hayakawa K. ADC mapping of benign and malignant breast tumors. Magn Reson Med Sci 2005, 4:35-42. 10.2463/mrms.4.35, 16127252.
27. Partridge SC, DeMartini WB, Kurland BF, Eby PR, White SW, Lehman CD. Differential diagnosis of mammographically and clinically occult breast lesions on diffusion-weighted MRI. J Magn Reson Imaging 2010, 31:562-570. 10.1002/jmri.22078, 20187198.
28. Bogner W, Gruber S, Pinker K, Grabner G, Stadlbauer A, Weber M, Moser E, Helbich TH, Trattnig S. Diffusion-weighted MR for differentiation of breast lesions at 3.0 T: how does selection of diffusion protocols affect diagnosis?. Radiology 2009, 253:341-351. 10.1148/radiol.2532081718, 19703869.
29. Ei Khouli RH, Jacobs MA, Mezban SD, Huang P, Kamel IR, Macura KJ, Bluemke DA. Diffusion-weighted imaging improves the diagnostic accuracy of conventional 3.0-T breast MR imaging. Radiology 2010, 256:64-73. 10.1148/radiol.10091367, 20574085.
30. Partridge SC, DeMartini WB, Kurland BF, Eby PR, White SW, Lehman CD. Quantitative diffusion-weighted imaging as an adjunct to conventional breast MRI for improved positive predictive value. AJR Am J Roentgenol 2009, 193:1716-1722. 10.2214/AJR.08.2139, 19933670.
31. Hatakenaka M, Soeda H, Yabuuchi H, Matsuo Y, Kamitani T, Oda Y, Tsuneyoshi M, Honda H. Apparent diffusion coefficients of breast tumors: clinical application. Magn Reson Med Sci 2008, 7:23-29. 10.2463/mrms.7.23, 18460845.
32. Pickles MD, Gibbs P, Lowry M, Turnbull LW. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 2006, 24:843-847. 10.1016/j.mri.2005.11.005, 16916701.
33. Sharma U, Danishad KK, Seenu V, Jagannathan NR. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed 2009, 22:104-113. 10.1002/nbm.1245, 18384182.
34. Nilsen L, Fangberget A, Geier O, Olsen DR, Seierstad T. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Acta Oncol 2010, 49:354-360. 10.3109/02841861003610184, 20397769.
35. Robinson SP, Howe FA, Rodrigues LM, Stubbs M, Griffiths JR. Magnetic resonance imaging techniques for monitoring changes in tumor oxygenation and blood flow. Semin Radiat Oncol 1998, 8:197-207. 10.1016/S1053-4296(98)80045-3, 9634496.
36. Li SP, Taylor NJ, Makris A, Ah-See ML, Beresford MJ, Stirling JJ, d'Arcy JA, Collins DJ, Padhani AR. Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy. Radiology 2010, 257:643-652. 10.1148/radiol.10100421, 20858850.
37. Alonzi R, Padhani AR, Maxwell RJ, Taylor NJ, Stirling JJ, Wilson JI, d'Arcy JA, Collins DJ, Saunders MI, Hoskin PJ. Carbogen breathing increases prostate cancer oxygenation: a translational MRI study in murine xenografts and humans. Br J Cancer 2009, 100:644-648. 2653742, 19190629, 10.1038/sj.bjc.6604903.
38. Tozaki M. Proton MR spectroscopy of the breast. Breast Cancer 2008, 15:218-223. 10.1007/s12282-008-0048-x, 18443899.
39. Huang W, Fisher PR, Dulaimy K, Tudorica LA, O'Hea B, Button TM. Detection of breast malignancy: diagnostic MR protocol for improved specificity. Radiology 2004, 232:585-591. 10.1148/radiol.2322030547, 15205478.
40. Jagannathan NR, Kumar M, Seenu V, Coshic O, Dwivedi SN, Julka PK, Srivastava A, Rath GK. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 2001, 84:1016-1022. 2363867, 11308247, 10.1054/bjoc.2000.1711.
41. Tozaki M, Sakamoto M, Oyama Y, Maruyama K, Fukuma E. Predicting pathological response to neoadjuvant chemotherapy in breast cancer with quantitative 1 H MR spectroscopy using the external standard method. J Magn Reson Imaging 2010, 31:895-902. 10.1002/jmri.22118, 20373434.
42. Tozaki M, Oyama Y, Fukuma E. Preliminary study of early response to neoadjuvant chemotherapy after the first cycle in breast cancer: comparison of 1 H magnetic resonance spectroscopy with diffusion magnetic resonance imaging. Jpn J Radiol 2010, 28:101-109. 10.1007/s11604-009-0391-7, 20182844.
43. Su MY, Baik HM, Yu HJ, Chen JH, Mehta RS, Nalcioglu O. Comparison of choline and pharmacokinetic parameters in breast cancer measured by MR spectroscopic imaging and dynamic contrast enhanced MRI. Technol Cancer Res Treat 2006, 5:401-410.
44. Thomas MA, Wyckoff N, Yue K, Binesh N, Banakar S, Chung HK, Sayre J, DeBruhl N. Two-dimensional MR spectroscopic characterization of breast cancer in vivo. Technol Cancer Res Treat 2005, 4:99-106.
45. Ouwerkerk R, Jacobs MA, Macura KJ, Wolff AC, Stearns V, Mezban SD, Khouri NF, Bluemke DA, Bottomley PA. Elevated tissue sodium concentration in malignant breast lesions detected with non-invasive 23Na MRI. Breast Cancer Res Treat 2007, 106:151-160. 10.1007/s10549-006-9485-4, 17260093.
46. Jacobs MA, Stearns V, Wolff AC, Macura K, Argani P, Khouri N, Tsangaris T, Barker PB, Davidson NE, Bhujwalla ZM, Bluemke DA, Ouwerkerk R. Multiparametric magnetic resonance imaging, spectroscopy and multinuclear ((2)(3)Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. Acad Radiol 2010, 17:1477-1485. 10.1016/j.acra.2010.07.009, 20863721.
47. McKnight AL, Kugel JL, Rossman PJ, Manduca A, Hartmann LC, Ehman RL. MR elastography of breast cancer: preliminary results. AJR Am J Roentgenol 2002, 178:1411-1417.
48. Siegmann KC, Xydeas T, Sinkus R, Kraemer B, Vogel U, Claussen CD. Diagnostic value of MR elastography in addition to contrast-enhanced MR imaging of the breast-initial clinical results. Eur Radiol 2010, 20:318-325. 10.1007/s00330-009-1566-4, 19727753.
49. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009, 86:97-100. 10.1038/clpt.2009.68, 19440188.
50. Lo GG, Ai V, Chan JK, Li KW, Cheung PS, Wong TT, Ma M, Lee R, Chien D. Diffusion-weighted magnetic resonance imaging of breast lesions: first experiences at 3 T. J Comput Assist Tomogr 2009, 33:63-69. 10.1097/RCT.0b013e318165dc6b, 19188787.
51. Azlan CA, Di GP, Ahearn TS, Semple SI, Gilbert FJ, Redpath TW. B1 transmission-field inhomogeneity and enhancement ratio errors in dynamic contrast-enhanced MRI (DCE-MRI) of the breast at 3T. J Magn Reson Imaging 2010, 31:234-239. 10.1002/jmri.22018, 20027594.
52. Mehta S, Li SP, Hughes NP, Adams RF, Padhani AR, Buffa FM, Wright CA, McRae LA, Makris A, Harris AL. Investigation of pathways regulating early antiangiogenic response to bevacizumab given prior to neoadjuvant breast cancer chemotherapy. J Clin Oncol 2010, 28(suppl; abstr TPS176):15s.